Home / Specialty Pharmacy (page 34)

Specialty Pharmacy

Specialty Pharma Journal (SPJ) and Specialty Pharma Education Center (SPEC) Partner for Business-Based Educational Programs in Specialty Pharmacy

Tampa, FL, February 24, 2015 — Specialty Pharma Journal (SPJ) announced today that it has partnered with the Specialty Pharma Education Center (SPEC) to bring business-based educational programs to the specialty pharmacy industry. SPJ and SPEC are developing programs dedicated to education in biosimilars, 340B contracting, co-pay and coupon adjudication guidelines in …

Read More »

CMS Tells Aetna to Implement Correction Action Plan to Comply with US Pharmacy Rules

US regulators ordered Aetna Inc. to fix its Medicare drug program after the company’s website inaccurately advertised that Aetna plan networks included pharmacies that were not in their network. The Centers for Medicare and Medicaid Services (CMS) has announced that more than 400,000 Medicare beneficiaries who were confused or misinformed …

Read More »

Roche’s Gazyva Succeeds in its Late-Stage Trial in Non-Hodgkin’s Lymphoma

Roche announced that it has ended its late-stage study evaluating its leukemia drug Gazyva earlier than expected following positive results. The company announced positive results from the Phase III GADOLIN study, which evaluated treatment options for patients with indolent non-Hodgkin’s lymphoma (NHL) who are refractory to MabThera/Rituxan (rituximab) treatment. After …

Read More »

Physician’s Offices and Clinics Remain Largest Customer Base for Specialty Rx Distributors

Center Research Highlights Latest Trends for Fast-Growing Specialty Market Segment ARLINGTON, Va., February 3, 2015 — Physician’s offices and independently owned and operated physician clinics remain the largest customer base for specialty pharmaceutical distributors, at 63 percent of their sales value, according to the2014 Specialty Pharmaceutical Distribution: Facts, Figures and …

Read More »

Genentech’s Investigational Monoclonal Antibody Granted Breakthrough Status for Treatment of Lung Cancer

US-based Genentech recently announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for its investigational cancer immunotherapy. The agency granted the designation to Genentech’s MPDL3280A for treatment of patients with Programmed Death-Ligand 1 (PD-L1) positive non-small cell lung cancer (NSCLC) whose disease has progressed during …

Read More »

Biogen Partners to Develop Gene Therapies for Hemophilia

Biogen Idec is teaming up with Fondazione Telethon and Ospedale San Raffaele to develop gene therapies for hemophilia A and B. The worldwide collaboration will combine San Raffaele-Telethon Institute for Gene Therapy’s (TIGET) extensive expertise in creating new gene therapy strategies and developing them from bench to bedside with Biogen’s …

Read More »

mHealth Tools Significantly Improve Adherence Among HIV Patients

New mobile health (mHealth) tools have demonstrated effectiveness in aiding HIV patients better manage their disease through improved medication adherence. After analyzing data regarding the effectiveness in mobile pharmacy apps in helping HIV patients, mscripts and Avella Specialty Pharmacy found that HIV patients using a mobile app which provides refill …

Read More »

FDA and EC Approve Novartis’ Psoriasis Drug Cosentyx

The US Food and Drug Administration (FDA) and the European Commission (EC) approved Novartis’ biologic Cosentyx (secukinumab) as a treatment for psoriasis. Today, Novartis announced that it has received FDA-approval and recently received EU approval for the drug, making it the first drug in the interleukin-17A (IL-17A) inhibitor class to …

Read More »

FDA Grants Fast Track Status to Marathon’s Duchenne Muscular Dystrophy Drug

Marathon Pharmaceuticals’ investigational Duchenne Muscular Dystrophy (DMD) drug was granted Fast Track designation by US health regulators. The rare-disease focused biopharmaceutical company recently announced that the US Food and Drug Administration (FDA) granted fast track status for its deflazacort for treatment of patients with DMD, a fatal muscle disease found …

Read More »

AbbVie’s Hepatitis C Drug Wins EC Approval

European regulators have approved AbbVie’s all-oral, interferon-free hepatitis C drug. The company announced today that the European Commission (EC) has granted marketing authorizations for Viekirax (ombitasvir/paritaprevir/ritonavir tablets) + Exviera (dasabuvir tablets) for treatment with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, including those with compensated liver cirrhosis, HIV-1 …

Read More »